Study design
A prospective, observational, longitudinal, single-center study was
conducted between May 2015 and June 2018 in the Department of Pediatric
Hematology of Gregorio Marañón Hospital, located in Madrid, Spain. The
study included 30 patients between 2 and 18 years old who underwent
allogeneic bone marrow transplantation and received prophylaxis with
micafungin on alternating days after the bone marrow engraftment phase.